Public Release: 7-Feb-2018
Cancer Research UK
Scientists have discovered that an amino acid called asparagine is essential for breast cancer spread, and by restricting it, cancer cells stopped invading other parts of the body in mice, according to research* part-funded by Cancer Research UK and published in the journal Nature today, (Wednesday).
Most breast cancer patients do not die from their primary tumour, but from the spread of cancer to the lungs, brain, bones, or other organs. To be able to spread, cancer cells first need to leave the original tumour, survive in the blood as ‘circulating tumour cells’, and then colonise other organs.
Finding ways to stop this from happening is fundamental to increasing survival.
Researchers at the Cancer Research UK Cambridge Institute found that blocking the production of asparagine with a drug called L-asparaginase in mice, and putting them on a low-asparagine diet, greatly reduced the breast cancer’s ability to spread.
Asparagine is an amino acid – the building blocks that cells use to make proteins. While the body can make asparagine, it’s also found in our diet, with higher concentrations in some foods including asparagus, soy, dairy, poultry, and seafood.
Researchers were prompted by these mouse studies to examine data from breast cancer patients. These data indicated that the greater the ability of breast cancer cells to make asparagine, the more likely the disease is to spread. In several other cancer types, increased ability of tumour cells to make asparagine was also found to be associated with reduced survival.
In future, the scientists believe that alongside conventional treatments like chemotherapy, breast cancer patients could be given a diet in hospital that restricts asparagine to help stop the disease spreading and improve outcomes. Their findings also suggest this could have implications for other cancer types, including kidney, and head and neck cancers.
Professor Greg Hannon, lead author of the study based at the Cancer Research UK Cambridge Institute, said: “Our work has pinpointed one of the key mechanisms that promotes the ability of breast cancer cells to spread. When the availability of asparagine was reduced, we saw little impact on the primary tumour in the breast, but tumour cells had reduced capacity for metastases in other parts of the body.
“This finding adds vital information to our understanding of how we can stop cancer spreading – the main reason patients die from their disease.
“In the future, restricting this amino acid through a controlled diet plan or by other means could be an additional part of treatment for some patients with breast and other cancers.”
Professor Charles Swanton, Cancer Research UK’s chief clinician, said: “This is interesting research looking at how cutting off the supply of nutrients essential to cancer’s spread could help restrain tumours.
“Interestingly, the drug L-asparaginase is used to treat acute lymphoblastic leukaemia which is dependent on asparagine. It’s possible that in future, this drug could be repurposed to help treat breast cancer patients.
“The next step in the research would be to understand how this translates from the lab to patients and which patients are most likely to benefit from any potential treatment.”
Martin Ledwick, Cancer Research UK’s head nurse, said: “Research like this is crucial to help develop better treatments for breast cancer patients. At the moment, there is no evidence that restricting certain foods can help fight cancer, so it’s important for patients to speak to their doctor before making any changes to their diet while having treatment.”
For media enquiries contact Stephanie McClellan in the Cancer Research UK press office on 020 3469 5314 or, out of hours, on 07050 264 059.
Notes to editor:
* Knott et al. Asparagine bioavailability governs metastasis in a model of breast cancer
This research received funding from The Hope Funds For Cancer Research, Human Frontier Science Program, Susan G. Komen Foundation, NCI Breast SPORE program, Breast Cancer Research Foundation, Triple Negative Breast Cancer Foundation, NIH, The Institute of Cancer Research, CRUK Grand Challenge Award, Cancer Research UK, and the DOD BCRP.
About Cancer Research UK
- Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
- Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no funding from the UK government for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK’s vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK’s work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.